These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2831815)

  • 1. Comparison of cefazolin, cefamandole, vancomycin, and LY146032 for prophylaxis of experimental Staphylococcus epidermidis endocarditis.
    Wheat LJ; Smith JW; Reynolds J; Bemis AT; Treger T; Norton JA
    Antimicrob Agents Chemother; 1988 Jan; 32(1):63-7. PubMed ID: 2831815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
    Stratton CW; Liu C; Weeks LS
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1210-5. PubMed ID: 2820300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.
    Archer GL; Vazquez GJ; Johnston JL
    J Infect Dis; 1980 Nov; 142(5):725-31. PubMed ID: 7462687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial prophylaxis of experimental endocarditis caused by Staphylococcus epidermidis.
    Baddour LM; Hill MM; Felty-Duckworth AM
    Infection; 1989; 17(2):90-6. PubMed ID: 2714864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of cephalosporins against coagulase-negative staphylococci.
    Chin NX; Neu NM; Neu HC
    Diagn Microbiol Infect Dis; 1990; 13(1):67-9. PubMed ID: 2331853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.
    Kennedy S; Chambers HF
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1522-5. PubMed ID: 2554799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of LY146032 against Staphylococcus aureus and S. epidermidis.
    Coudron PE; Johnston JL; Archer GL
    J Antimicrob Chemother; 1987 Oct; 20(4):505-11. PubMed ID: 2824426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population analysis of susceptibility to methicillin, vancomycin, and three cephalosporines in two methicillin-resistant strains of Staphylococcus epidermidis.
    Hansen BG
    Acta Pathol Microbiol Immunol Scand B; 1983 Aug; 91(4):279-84. PubMed ID: 6556002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic therapy of experimental Staphylococcus epidermidis endocarditis.
    Vazquez GJ; Archer GL
    Antimicrob Agents Chemother; 1980 Feb; 17(2):280-5. PubMed ID: 7387148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide Organism Susceptibility Patterns to Common Preoperative Prophylactic Antibiotics: What Are We Covering?
    Nodzo SR; Boyle KK; Frisch NB
    J Arthroplasty; 2019 Jul; 34(7S):S302-S306. PubMed ID: 30745218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
    García-de-la-Mària C; Marco F; Armero Y; Soy D; Moreno A; del Río A; Almela M; Cervera C; Ninot S; Falces C; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2781-6. PubMed ID: 20421394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility and synergy studies of methicillin-resistant Staphylococcus epidermidis.
    Ein ME; Smith NJ; Aruffo JF; Heerema MS; Bradshaw MW; Williams TW
    Antimicrob Agents Chemother; 1979 Nov; 16(5):655-9. PubMed ID: 260880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipenem therapy of experimental Staphylococcus epidermidis endocarditis.
    Berry AJ; Johnston JL; Archer GL
    Antimicrob Agents Chemother; 1986 May; 29(5):748-52. PubMed ID: 3460523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inoculum effect on growth-delay time of oxacillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis exposed to cefamandole, cefazolin, and cefuroxime.
    Yourassowsky E; van der Linden MP; Crokaert F
    Antimicrob Agents Chemother; 1990 Apr; 34(4):505-9. PubMed ID: 2344158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.
    Mader JT; Adams K
    Antimicrob Agents Chemother; 1989 May; 33(5):689-92. PubMed ID: 2546488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporin A as a prophylactic agent against methicillin sodium-susceptible and methicillin sodium-resistant Staphylococcus epidermidis vascular graft infection.
    Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; Kamysz W; Del Prete MS; Lukasiak J; Scalise G; Saba V
    J Vasc Surg; 2002 Nov; 36(5):1027-30. PubMed ID: 12422090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits.
    Carrizosa J; Kobasa WD; Kaye D
    Antimicrob Agents Chemother; 1980 Oct; 18(4):562-5. PubMed ID: 7447418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children.
    Kline MW; Mason EO; Kaplan SL; Lamberth LB; Johnson GS
    J Antimicrob Chemother; 1987 Aug; 20(2):203-7. PubMed ID: 2822647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal action of nafcillin, vancomycin, and three cephalosporins against nafcillin-susceptible and nafcillin-resistant coagulase-negative staphylococci.
    Mordenti JJ; Davis RH; Lammel CJ; Brooks GF
    Diagn Microbiol Infect Dis; 1986 May; 5(1):1-8. PubMed ID: 3635453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial.
    Maki DG; Bohn MJ; Stolz SM; Kroncke GM; Acher CW; Myerowitz PD
    J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1423-34. PubMed ID: 1434726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.